{"id":83637,"date":"2020-04-18T00:55:03","date_gmt":"2020-04-18T03:55:03","guid":{"rendered":"https:\/\/megalabs.global\/eng\/?p=83637"},"modified":"2020-04-23T18:44:40","modified_gmt":"2020-04-23T21:44:40","slug":"interferon-beta-1a","status":"publish","type":"post","link":"https:\/\/megalabs.global\/eng\/interferon-beta-1a\/","title":{"rendered":"Interfer\u00f3n beta-1A"},"content":{"rendered":"

[vc_row row_height_percent=”0″ override_padding=”yes” h_padding=”2″ top_padding=”3″ bottom_padding=”3″ overlay_alpha=”100″ gutter_size=”3″ shift_y=”0″ row_height_use_pixel=””][vc_column column_width_use_pixel=”yes” gutter_size=”3″ overlay_alpha=”50″ shift_x=”0″ shift_y=”0″ medium_width=”0″ zoom_width=”0″ zoom_height=”0″ column_width_pixel=”800″][vc_column_text]El Interfer\u00f3n-beta-1 A est\u00e1 indicado para el tratamiento de formas recurrentes de esclerosis m\u00faltiple (EM), que incluye s\u00edndrome cl\u00ednicamente aislado, enfermedad recurrente y enfermedad secundaria activa progresiva, en adultos. Fue aprobado por la Agencia estadounidense en el a\u00f1o 2002. (2)<\/p>\n

Dosis y administraci\u00f3n propuestas para COVID-19 (1)<\/strong>
\nAdultos<\/strong><\/em>
\n5 millones de unidades agregando 2 mL de suero est\u00e9ril, dos veces al d\u00eda inhalado. Nebulizaci\u00f3n con interfer\u00f3n-\u03b12b 100.000\u2013200.000 UI\/kg para casos leves, y 200.000\u2013400.000 UI\/kg para casos graves, dos veces al d\u00eda durante 5\u20137 d\u00edas.
\nPedi\u00e1trica<\/strong><\/em>
\nNebulizaci\u00f3n de 100.000-200.000 UI\/kg para casos leves; 200.000-400.000 UI\/kg en casos graves, dos veces \/ d\u00eda durante 5-7 d\u00edas<\/p>\n

Precauciones y advertencias (2)<\/strong>
\n\u2022 Depresi\u00f3n y suicidio: se aconseja discontinuar el tratamiento ante sintomas de depresi\u00f3n.
\n\u2022 Lesi\u00f3n hep\u00e1tica: se recomienda controlar las pruebas de funci\u00f3n hep\u00e1tica; vigilar a los pacientes en busca de signos y s\u00edntomas de lesi\u00f3n hep\u00e1tica; considere suspender REBIF si la lesi\u00f3n hep\u00e1tica ocurre
\n\u2022 Anafilaxia y otras reacciones al\u00e9rgicas:
\n\u2022 Reacciones en el lugar de inyecci\u00f3n, incluida la necrosis:
\n\u2022 Disminuci\u00f3n de los recuentos sangu\u00edneos perif\u00e9ricos: controle los recuentos sangu\u00edneos completos
\n\u2022 Microangiopat\u00eda tromb\u00f3tica
\n\u2022 Convulsiones: se recomienda controlar las convulsiones, particularmente aquellos con trastornos convulsivos preexistentes<\/p>\n

Eventos adversos<\/strong>
\nAnorexia, depresi\u00f3n, insomnio, ansiedad, labilidad emocional, mareo, cefalea, n\u00e1useas, v\u00f3mitos, diarrea, dolor abdominal, alopecia, rash, mialgia, artralgia, dolor musculoesquel\u00e9tico, inflamaci\u00f3n y reacci\u00f3n en punto de inyecci\u00f3n, fatiga, rigidez, pirexia, s\u00edntomas pseudogripales, malestar general, irritabilidad
\nEntre las reacciones adversas notificadas con mayor frecuencia para este medicamento se encuentran los s\u00edntomas similares a la gripe (ocurri\u00f3 en 59% de los participantes del estudio cl\u00ednico realizado para Rebif con una dosis de 44mcg) y elevaciones en las enzimas hep\u00e1ticas.<\/p>\n

Estudios cl\u00ednicos con COVID-19<\/strong>
\n\u2022 Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy). (17)[\/vc_column_text][vc_single_image media=”83639″ media_width_use_pixel=”yes” alignment=”center” media_width_pixel=”710″][vc_column_text]\u2022 Experimental Trial of rhIFN\u03b1 Nasal Drops to Prevent 2019-nCOV in Medical Staff. (29)[\/vc_column_text][vc_single_image media=”83640″ media_width_use_pixel=”yes” alignment=”center” media_width_pixel=”712″][vc_column_text]\u2022 Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treat-ment\/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19). (30)[\/vc_column_text][vc_single_image media=”83641″ media_width_use_pixel=”yes” alignment=”center” media_width_pixel=”712″][vc_column_text]\u2022 Lopinavir\/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment. (20)[\/vc_column_text][vc_single_image media=”83642″ media_width_use_pixel=”yes” alignment=”center” media_width_pixel=”712″][vc_column_text]Link a informaci\u00f3n del producto de FDA:
\nwww.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/103780s5204lbl.pdf<\/a><\/p>\n

(1) Tratamientos disponibles para el manejo de la infecci\u00f3n respiratoria por SARS-CoV-2. AEMPS2020.
\nAvailable from: https:\/\/www.aemps.gob.es\/la-aemps\/ultima-informacion-de-la-aemps-acerca-del-covid%e2%80%9119\/tratamientos-disponibles-para-el-manejo-de-la-infeccion-respiratoria-por-sars-cov-2\/<\/a>.<\/p>\n

(2) Inserto Rebif Food and Drug Administration2019.
\nAvailable from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/103780s5204lbl.pdf<\/a>.<\/p>\n

(3) Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy). 2020.
\nAvailable from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04315948<\/a>.<\/p>\n

(4) Experimental Trial of rhIFN\u03b1 Nasal Drops to Prevent 2019-nCOV in Medical Staff 2020.
\nAvailable from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04320238<\/a>.<\/p>\n

(5) Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment\/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneu-monia (COVID-19) 2020.
\nAvailable from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04273763<\/a>.<\/p>\n

(6) Lopinavir\/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment 2020.
\nAvailable from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04276688<\/a>.[\/vc_column_text][vc_empty_space empty_h=”3″][vc_row_inner row_inner_height_percent=”0″ overlay_alpha=”50″ gutter_size=”3″ border_color=”color-877404″ border_style=”solid” shift_y=”0″ z_index=”0″ css=”.vc_custom_1572995729128{border-top-width: 1px !important;border-bottom-width: 1px !important;padding-top: 18px !important;padding-bottom: 18px !important;}” el_class=”descarga-pdf” limit_content=””][vc_column_inner width=”1\/1″][vc_icon position=”left” icon_image=”82110″ icon_color=”color-877404″ media_size=”42″ text_font=”font-195522″ text_weight=”700″ linked_title=”yes” title=”Descargar Documento” link=”url:%2Fwp-content%2Fuploads%2F2020%2F04%2FConexion_Interferon-beta.pdf|title:Conexion_Interferon%20beta|target:%20_blank|”]Conexion_Interferon beta[\/vc_icon][\/vc_column_inner][\/vc_row_inner][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Inyectable<\/p>\n","protected":false},"author":1,"featured_media":80575,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[94],"tags":[],"class_list":["post-83637","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-farmacos"],"_links":{"self":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/posts\/83637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/comments?post=83637"}],"version-history":[{"count":0,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/posts\/83637\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/media\/80575"}],"wp:attachment":[{"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/media?parent=83637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/categories?post=83637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/megalabs.global\/eng\/wp-json\/wp\/v2\/tags?post=83637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}